Andrographolide reduced HCT116 cell migration and invasion at 5 μM over 30 h. These in vitro observations should not be equated with demonstrated antimetastatic efficacy in vivo. [1]
Covalent modification of recombinant NF-κB p50
Biochemical assay · Recombinant NF-κB p50 protein; parent compound versus DMSO control [1]
LC-MS/MS identified an andrographolide-modified Cys62-containing peptide. This supports direct covalent target engagement, without establishing a binding constant or target selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- As reported: 1 μL of 10 mM andrographolide stock with 50 μg p50 in 100 μL PBS.
- Exposure duration
- 4 h at room temperature
- Method
- Incubation with recombinant protein before LC-MS/MS mapping
- Vehicle
- DMSO control; final solvent percentage not explicitly given for this experiment.
- Reported limits
- Replicate count and uncertainty of adduct detection not specified in the selected text; no affinity or inhibitory-potency measurement in this experiment.
Methods and source locations
Compound reported in the paper: Andrographolide; Compound label in the paper: Andro
Published parent-compound evidence; does not validate Adooq material, the reduced analogue or clickable probes.
Experimental Procedures, p50 binding-site mapping by MS/MS; Materials and Reagents; Figs. 2 and 5D; Target Validation and Functional Analysis
Modification of the Cys62-containing p50 peptide: LC-MS/MS after parent-compound incubation and tryptic digestion — Fig. 5D, mass-shift annotation; Target Validation and Functional Analysis, parent p50 MS/MS paragraph
HCT116 migration and invasion
Cell-based study · Human HCT116 colorectal cancer cells; DMSO and reduced analogue RA comparator groups [1]
At 5 μM for 30 h, andrographolide reduced migration through fibronectin-coated inserts and invasion through Matrigel-coated inserts relative to DMSO. These cellular endpoints do not demonstrate reduced metastasis in animals.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 30 h
- Method
- Exposure during migration/invasion assays
- Vehicle
- 1% DMSO negative control explicitly stated for migration; Fig. 7 also labels a DMSO invasion control, without a separately specified solvent percentage.
- Co-treatment
- None; RA (5 μM) was a separate comparator.
- Reported limits
- Biological replicate number, error-bar definition and statistical test for Fig. 7 are not specified in the selected methods/legend. No numerical bar heights inferred. The authors describe 5 μM as noncytotoxic, but a matched 30 h viability control was not independently verified.
Methods and source locations
Compound reported in the paper: Andrographolide; Compound label in the paper: Andro
Published parent-compound evidence; does not validate Adooq material, the reduced analogue or clickable probes.
Materials and Reagents; Transwell Migration Assay; Matrigel Invasion Assay; Target Validation and Functional Analysis, migration/invasion paragraph; Fig. 7A–C
Migration toward serum-containing medium: Transwell migration, crystal-violet signal at 550 nm — Transwell Migration Assay; Fig. 7A–B and legend
Invasion through Matrigel: Cells counted in five randomly selected microscopy fields — Matrigel Invasion Assay; Fig. 7A,C and legend